Advanced Search

 

Study ID Status Title Patient Level Data
VEG110727 Completed A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
VEG20002 Completed Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma
VEG20006 Completed A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients with Relapsed or Refractory Multiple Myeloma
VEG20007 Completed A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or Metastatic Breast Cancer with ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors
VIA-001 Completed Cost-effectiveness of a combination of Fluticasone Propionate and Salmeterol Xinafoate in comparison with conventional therapies of bronchial asthma (VIANI Real life).
VIA-002 Completed Viani® forte Discus® Post Marketing Surveillance Study.
VIN10003 Completed The Phase I Absolute Bioavailability Study of Oral NAVELBINE (vinorelbine tartrate) in Patients with Solid Tumors.
VIN10004 Completed An Open-Label Study to Provide Continuing Treatment with NAVELBINE (vinorelbine tartrate) Soft Gelatin Capsules or Injection to Subjects with Solid Tumors.
VINA1001 Completed A Phase I, Open-Label, Randomized, Crossover Study of Oral and Intravenous NAVELBINE (vinorelbine tartrate) in Subjects with Malignant Solid Tumors and Varying Degrees of Hepatic Function.
VINA2004 Completed A Phase II, Open-Label, Prospective, Randomized, Controlled, Multicenter Study of Single Agent NAVELBINE (vinorelbine tartrate) Administered Orally or Administered Intravenously for the Treatment of Chemotherapy-Naïve Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) and Chemotherapy- Na ...
VLX103596 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection. Study Listed on ClinicalStudyDataRequest.com
VLX105832 Completed The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection Study Listed on ClinicalStudyDataRequest.com
VRA105345 Completed A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar tooth extraction
VRA107438 Terminated A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal hypersensitivity including irritable bowel syndrome.
VRX-RET-E22-101 Completed Single-Dose Pharmacokinetics of Retigabine in Healthy Subjects and Patients with Various Degrees of Renal Insufficiency Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-101SR Completed Open-Label, Single-Dose, 8-Period Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a 400 mg Dose of Retigabine Sustained-Release Formulations in Seven Dosing Periods Versus a 200 mg Dose of Retigabine Immediate-Release Formulation in One Dosing Period in Healthy Adult Male Subjects Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-102 Completed Single-Dose Pharmacokinetics Study of Retigabine in Patients with Various Degrees of Hepatic Impairment Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-103 Completed A Double-Blind Randomized Parallel-group Trial to Define the ECG Effects of Retigabine Using a Maximum Tolerated Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-104 Completed Comparative, Randomized, Open-Label, Single-Dose, 2-way Crossover Food Effect, Safety and Tolerability Study of a 400-mg Dose of the Retigabine Market Image Tablet in Healthy Adult Male Subjects Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-105 Completed Comparative, Randomized, Open-Label, Single-Dose, 2-Way Crossover Bioavailability, Safety and Tolerability Study of a 400mg Dose of Retigabine Administered as the Clinical Trials Formulation and the Market Image Formulation in Healthy Adult Male Subjects Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-106 Completed A Pharmacokinetic Interaction Study Evaluating the Effect of Repeated Retigabine Dosing on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Volunteers Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-107 Completed A Randomized, Partially Double-Blind, Four-Way Crossover Study to Determine the Effects of a Single Dose of Retigabine Combined with a Single Dose of Alcohol Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-108 Completed A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Retigabine in Recreational Polydrug Users Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-301 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-302 Completed Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.